|April 22, 2013|
|10:20 EDT||USG, PRGO, JCI, EADSY, BZH, VFC, NFLX, BRD, MIG, HES, EQIX, BHP, HXL, AAPL, AEM, SKX, MDC, FHN, CIR, ABBV, VMI, LBAI||On The Fly: Analyst Upgrade Summary|
Today's noteworthy upgrades include: AbbVie (ABBV) upgraded to Overweight from Equal Weight at Morgan Stanley... BHP Billiton (BHP) upgraded to Overweight from Neutral at HSBC... Beazer Homes (BZH) upgraded to Outperform from Neutral at Credit Suisse... CIRCOR (CIR) upgraded to Buy from Hold at BB&T... EADS (EADSY) upgraded to Outperform from Sector Perform at RBC Capital... Equinix (EQIX) upgraded to Overweight from Equal Weight at Stephens... First Horizon (FHN) upgraded to Neutral from Sell at Compass Point... Hess Corp. (HES) upgraded to Overweight from Equal Weight at Barclays... Johnson Controls (JCI) upgraded to Outperform from Neutral at RW Baird... M.D.C. Holdings (MDC) upgraded to Neutral from Underperform at Credit Suisse... Meadowbrook Insurance (MIG) upgraded to Outperform at Keefe Bruyette... Perrigo (PRGO) upgraded to Overweight from Neutral at JPMorgan... Skechers (SKX) upgraded to Buy from Hold at BB&T... USG (USG) upgraded to Neutral from Underperform at Credit Suisse... Brigus Gold (BRD) upgraded to Buy from Neutral at Global Hunter... Agnico-Eagle (AEM) upgraded to Buy from Neutral at Global Hunter... Netflix (NFLX) upgraded to Neutral from Sell at B. Riley... Apple (AAPL) upgraded to Buy from Hold at BGC Partners... Lakeland Bancorp (LBAI) upgraded to Outperform from Neutral at Macquarie... VF Corp. (VFC) upgraded to Outperform from Neutral at Wedbush... Valmont (VMI) upgraded to Outperform from Neutral at Wedbush... Hexcel (HXL) upgraded to Outperform from Sector Perform at RBC Capital.
News For ABBV;BHP;BZH;CIR;EQIX;EADSY;FHN;HES;JCI;MDC;MIG;PRGO;SKX;BRD;USG;AEM;NFLX;LBAI;AAPL;VFC;VMI;HXL From The Last 14 Days
|September 21, 2015|
|14:04 EDT||ABBV||Clinton vow to end drug price gouging sinks biotechs|
Biotech stocks have declined across the board in afternoon trading following a tweet by Presidential candidate Hillary Clinton criticizing the "outrageous" prices of specialty drugs. TURING STEPS UP PRICING: Clinton's tweet directly referenced Turing Pharmaceuticals' Daraprim treatment for toxoplasmosis, which recently had its price hiked from just $13.50 per pill to $750 after the privately-held company acquired the drug from Impax Laboratories (IPXL). Importantly, Daraprim was first approved by the FDA in 1953 and its patents have long since expired. No generic versions of the drug currently exist, perhaps in part due to Turing executive chairman Martin Shkreli's strategy of tightly controlling distribution, according to a New York Post article on the issue. In a Bloomberg TV interview this morning, Shkreli claimed that the drug remains underpriced compared to what he called its peers in the rare disease space. However, note that a World Health Organization analysis from 2013 reported that over 190,000 cases of toxoplasmosis occur globally every year and Daraprim continues to be listed on the organization's list of essential medicines for a basic health-care system. INDUSTRY CRITICISM: Turing's Daraprim pricing prompted a response from the Infectious Diseases Society of America and the HIV Medicine Association, which criticized the "unjustifiable" new cost of the drug and urged a "rational" pricing strategy. The news surrounding Daraprim also comes on the heels of Presidential candidate Bernie Sanders issuing a letter in August to Valeant (VRX) and Hospira (HSP), in which he requested information on the "enormous" price increases of two drugs Valeant acquired earlier in the year. REPUBLICAN CONGRESS: In a research note released this afternoon, RBC Capital analyst Michael Yee reminded investors that Republicans still control Congress, offering a sobering reminder that campaign trail promises often fall by the wayside once the candidate steps into office. Yee explained that, though drug pricing debates during next year's election will probably generate headline risk for the biotech space, the Republican-controlled Congress is unlikely to sign into law any material changes on the issue. BIOTECH STOCK ACTION: Hillary Clinton's promise to "lay out a plan" tomorrow to tackle "price gouging" in the specialty drug market sent numerous biotech stocks plunging. Aerie Pharmaceuticals (AERI) has crashed 12.6% at time of writing, while Retrophin (RTRX), Ultragenyx (RARE), and PTC Therapeutics (PTCT) are down 14.7%, 13.4%, and 11%, respectively. Biotech giants AbbVie (ABBV), Gilead (GILD), Bristol-Myers Squibb (BMY) and Biogen (BIIB) have also slipped in intraday trading, while the NASDAQ Biotechnology index is down roughly 4%.
|13:52 EDT||AAPL||Tesla options active on Apple accelerates electric-car plan report|
Tesla (TSLA) September weekly 255 and 260 puts are active on total put volume of 48K contracts (49K calls) following the WSJ's report Apple (AAPL) accelerates electric-car plan, targets shipment in 2019. September weekly put option implied volatility is at 47, October is at 46; compared to its 52-week range of 29 to 62. Active options volume suggests traders taking positions for large price movement.
|13:47 EDT||AAPL||Apple accelerates electric car plan, WSJ reports|
Subscribe for More Information
|13:43 EDT||AAPL||Apple accelerates electric-car plan, targets shipment in 2019, WSJ reports|
Shares of electric car maker Tesla (TSLA) have moved into negative ground following the Journal's report. Reference Link
|13:31 EDT||NFLX||After Emmys, analyst sees 'growing threat' to established content creators|
Netflix (NFLX), Time Warner (TWX), and Viacom (VIA) shares fell in midday trading following last night's Emmy Awards, while Amazon (AMZN) climbed. An analyst called the combined nominations for Netflix and Amazon a an indication that emerging over-the-top streaming services have become a "growing threat to the establishment." WHAT'S NEW: HBO, a Time Warner network, dominated the 67th Annual Emmy Awards, walking away with 43 awards overall, including 29 Creative Emmys, while Netflix won four awards, as did Viacom's Comedy Central. Amazon, meanwhile, achieved its first-ever Emmy wins with five total awards. Following HBO's performance at the annual awards show, Netflix Chief Executive Officer Reed Hastings tweeted: "Congrats @HBO on supporting so much Emmy-winning talent. Your leadership of great television is inspiring." Netflix was nominated for 34 awards, while Amazon was nominated for 12. STREET RESEARCH: Cantor Fitzgerald analyst Youssef Squali said that while Netflix's four Emmys this year was "somewhat disappointing" considering last year's seven, the service's performance at the awards show was "notable," particularly since the company has long been underestimated by bigger and more established content creators. Squali said that the combined 46 nominations for both Netflix and Amazon is a "clear indication" that emerging over-the-top streaming services have become a "growing threat to the establishment" and that it's "a matter of time" before such services begin to rival and possibly exceed their "linear cousins." The analyst sees Netflix gaining strong momentum heading into the second half of fiscal 2015 and 2016 and reiterated a Buy rating on the company's stock with a $125 price target. PRICE ACTION: Netflix shares are down 1.95% to $100.62 in afternoon trading. Meanwhile, Time Warner is down 0.29% to $69.44, Viacom is down 2.42% to $45.58, and Amazon is up 0.94% to $545.32.
|13:17 EDT||ABBV||RBC reminds biotech investors that Republicans still control Congress|
RBC Capital analyst Michael Yee notes that biotech indices are under pressure after Hillary Clinton tweeted about an upcoming plan to fight specialty drug pricing. The news follows a Wall Street Journal story about a private company dramatically increasing the price of their drug and another confirmed progressive multifocal leukoencephalopathy case for Biogen (BIIB), Yee tells investors in an intraday research note. Next year's election is likely to turn up the noise around drug pricing, creating headline risk for the biotech space, the analyst cautions. However, he reminds investors that Republicans control Congress, making it unlikely that "anything material" will get signed into law. Biotech names moving lower in today's trading include Biogen, AbbVie (ABBV), Gilead (GILD), Alkermes (ALKS), BioMarin (BMRN), Amicus (FOLD) and PTC Therapeutics (PTCT).
|12:55 EDT||NFLX||On The Fly: Top stock stories at midday|
Stocks began the session with a triple digit gain for the Dow and remained in a fairly narrow range for most of the morning. However, once the European markets closed, the U.S. averages weakened and are now struggling to remain in positive ground. ECONOMIC EVENTS: In the U.S., existing home sales fell 4.8% to a 5.31M rate in August, versus expectations for them to be down 1.6% to a rate of 5.5M. Over the weekend, three Federal Reserve officials, namely an Francisco Fed President John Williams, St. Louis Fed President James Bullard and Richmond Fed President Jeffrey Lacker, all argued that an interest-rate increase is still warranted this year. In Europe, Alexis Tsipras' Syriza party gained 35.5% of the vote in the Greek election. COMPANY NEWS: Shares of Volkswagen (VLKAY) trading in Germany plunged and the ADRs trading in New York dropped more than 17.5% after the EPA and California Air Resources Board detected manipulations that violate American environmental standards while testing Volkswagen diesel cars. The EPA said Volkswagen may face civil penalties of $37,500 for each vehicle not in compliance with federal clean air rules, which could total as much as $18B, according to Reuters... Time Warner's (TWX) HBO dominated the Emmy awards ceremony with 43 awards, including the 29 Creative Emmys it won last week. Meanwhile, Amazon (AMZN) earned its first-ever Emmy wins and Netflix (NFLX) CEO Reed Hastings, whose company won four awards, tweeted out: "Congrats @HBO on supporting so much Emmy-winning talent. Your leadership of great television is inspiring." MAJOR MOVERS: Among the notable gainers was Atmel (ATML), which jumped 12% after agreeing to be acquired by German chipmaker Dialog Semiconductor in a deal valued at approximately $4.6B, or the equivalent of $10.42 per Atmel share. Among the noteworthy losers was Mallinckrodt (MNK), which dropped 9% following the announcement that ANI Pharmaceuticals (ANIP) plans to acquire two new drug applications from Merck (MRK) that could compete with Acthar, Mallinckrodt's largest product. Also lower was uniQure (QURE), which fell 15% after announcing topline results of one-year follow-up data from a Phase I/II clinical trial in four Sanfilippo B syndrome patients. Both stocks were among the many big pharma and biotech decliners after Hillary Clinton, on the heels of a Wall Street Journal report detailing Turing Pharmaceuticals' price hike to $750 from $13.50 per pill of a drug that treats a life-threatening parasitic infection, vowed to lay out a plan tomorrow to take on what she calls "price gouging" of specialty drugs. INDEXES: Near midday, the Dow was up 38.57, or 0.24%, to 16,423.15, the Nasdaq was down 21.13, or 0.44%, to 4,806.10, and the S&P 500 was up 1.85, or 0.09%, to 1,959.88.
|11:51 EDT||NFLX||Stocks with call strike movement; TWTR NFLX|
Subscribe for More Information
|11:14 EDT||NFLX||Netflix gaining momentum after last night's Emmy's, says Cantor|
Netflix (NFLX) left last night's 67th Emmy Awards with four trophies and Amazon (AMZN) "a surprising" five, Cantor Fitzgerald analyst Youssef Squali points out in a research note to investors. Netflix's performance is "somewhat disappointing" relative to last year's seven emmys, but it's still a "notable performance" for an $8.99 per month service that started in 2012, Squali argues. The combined 46 nominations for Netflix and Amazon is a "clear indication" that over-the-top streaming services are a "growing threat to the establishment," Squali writes. The analyst views this phenomenon, coupled with solid reviews for Narcos, ongoing expansion throughout Asia and a recent price hike in major European markets as signs Netflix is seeing strong momentum into the second half of 2015. He reiterates a Buy rating on the stock with a $125 price target. Netflix is up 15c to $102.71 in late morning trading.
|10:49 EDT||AAPL||GoPro falls after Barron's predicts 'dramatic' drop in share price|
GoPro (GPRO) shares fell in morning trading after an article from Barron's argued that the company's share price may drop to as low as $25. WHAT'S NEW: Alexander Eule argued in a Barron's article that GoPro's stock price may see a "dramatic" slip of as much as 30% to $25 due to significant competitive pressure from Apple (AAPL), Sony (SNE) and others. Eule noted that the company's shares have crashed to a recent $35 after peaking at $98 in October 2014 and even called the mostly bullish analyst views on the camera maker's stock "wishful thinking." Additionally, Eule called the company's cameras a "one-product wonder" and compares them to BlackBerry (BBRY) smartphones and Palm digital organizers, which previously dominated their respective markets. The article adds that there is risk in being overly bearish on the company, since the "impressive" brand might become an acquisition target. WHAT'S NOTABLE: Last Wednesday, Citi analyst Jeremy David said that GoPro chief financial officer Jack Lazar confirmed at the bank's Global Tech Conference the week before that the Hero4 Session camera has been off to a slow start since its launch on July 12. David said that the recent selloff in the company's shares has been motivated by investor concerns about the Session. At the time, Citi cut its third quarter fiscal 2015 estimate for the company to $425M from $438M and fourth quarter estimate to $560M from $737M, $148M below consensus estimate at the time of $708M. David also said he was reducing estimates for the second half of fiscal 2015 and first quarter of fiscal 2016 as a result of downside from the Hero4 Session, but left estimates after 1Q16 unchanged, saying the long-term fundamentals of the company are "intact." The analyst added that his firm was "humbled" by the recent move in share price and acknowledged that GoPro is the "quintessential product cycle stock," though he said he remains bullish on the long-term prospects of the camera maker and reiterated a $90 price target. David argued that GoPro missing Q3 estimates and guiding below the consensus for Q4 is largely priced in. Separately, The Wall Street Journal said on September 13 that shares of GoPro were starting to look like a bargain after dropping 50% in a month. The company had a difficult time selling its Hero4 Session camera in July in the face of competition from older GoPro models, the publication added. PRICE ACTION: In morning trading, GoPro shares are down 5.15% to $33.34. OTHERS TO WATCH: Ambarella (AMBA), which supplies chips to GoPro, is down 3.7% to $68.81.
|09:40 EDT||NFLX, AAPL||Active equity options trading on open|
Active equity options trading on open: AAPL BAC ESV BABA FB NFLX TSLA TWTR GE GPRO JPM ONVO MU
|09:14 EDT||NFLX||Netflix CEO congratulates HBO on Emmy dominance|
Netflix (NFLX) CEO Reed Hastings tweeted out: "Congrats @HBO on supporting so much Emmy-winning talent. Your leadership of great television is inspiring." Time Warner's (TWX) HBO dominated the Emmy awards ceremony with 43 awards over all, including 29 Creative Emmys last week. Viacom's (VIA) Comedy Central, with four wins, was the network with the second-highest number of awards last night. Meanwhile, Hastings' won Netflix won four awards and Amazon (AMZN) earned its first-ever Emmy wins with two awards for its series "Transparent." Reference Link
|08:31 EDT||AAPL||Apple says iPhone 6s, iPhone 6s Plus to arrive on Friday, September 25|
Apple announced iPhone 6s and iPhone 6s Plus will be available at 8:00 a.m. local time on Friday, September 25 at Apple's retail stores. Stores will have the new iPhones available for walk-in customers who are encouraged to arrive early. Both models will also be available on Friday from AT&T, Sprint, T-Mobile, Verizon Wireless, additional carriers and select Apple Authorized Resellers. Apple also announced the fastest iOS adoption ever, with more than 50 percent of devices already using iOS 9. Apple says "iPhone 6s and iPhone 6s Plus bring a powerful new dimension to iPhone's revolutionary Multi-Touch(TM) interface with 3D Touch, which senses how deeply you press the display, letting you do essential things more quickly and simply. The new iPhones introduce Live Photos, which bring still images to life, transforming instants frozen in time into unforgettable living memories. Live Photos, 3D Touch, 12-megapixel iSight camera, 5-megapixel FaceTime HD camera with Retina Flash and more are powered by the Apple-designed A9 chip, the most advanced chip ever in a smartphone, delivering faster performance and great battery life. iPhone 6s and iPhone 6s Plus are designed with the strongest glass on any smartphone and 7000 series aluminum, the same alloy used in the aerospace industry, in gorgeous metallic finishes that now include rose gold."
|08:22 EDT||AAPL||Apple survey suggests strong iPhone demand, says Baird|
Subscribe for More Information
|07:43 EDT||AAPL||Apple surveys indicate iPhone increasing high-end share, says Canaccord|
Subscribe for More Information
|06:34 EDT||AAPL||Samsung may be planning leasing program for Galaxy phones, Forbes reports|
Samsung (SSNLF) is rumored to be planning to launch a leasing program for its Galaxy phones in the U.S., similar to the program Apple (AAPL) recently announced, Forbes reports, citing an industry executive with knowledge of Samsung's plans. According to the source, Samsung could launch the leasing program in the next few months. Apple's iPhone Upgrade Program encourages consumers to buy iPhones directly from the Apple Store instead of going through carriers, the publication notes. Publicly traded wireless carriers include AT&T (T), Verizon (VZ), Sprint (S) and T-Mobile US (TMUS). Reference Link
|06:24 EDT||AAPL||Foxconn seeks to acquire Sharp's LCD business, Nikkei reports|
Taiwan's Hon Hai Precision Industry, better known as Foxconn (HNHPF) has offered to buy Sharp's (SHCAY) struggling LCD business and plans to seek funding from Apple (AAPL), a key Sharp customer, The Nikkei reports. According to the report, Foxconn would take a majority stake in a LCD company spun off by Sharp, with Apple also making an investment. Reference Link
|06:07 EDT||AAPL||Apple hit by rare malware in China, Financial Times reports|
Subscribe for More Information
|06:07 EDT||AAPL||Apple meets with regulators to discuss self-driving cars, Financial Times says|
Subscribe for More Information
|05:46 EDT||PRGO||Mylan reinstated with an Equal Weight at Barclays|
Barclays analyst Douglas Tsao reinstated Mylan (MYL) with an Equal Weight rating and $57 price target. The analyst expects uncertainty around the company's tender offer for Perrigo (PRGO) to weigh on the shares over the near term.